PubRank

Jörg Wischhusen

Author PubWeight™ 49.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007 6.21
2 Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008 2.84
3 SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004 2.35
4 O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006 2.08
5 RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004 1.83
6 Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 2010 1.76
7 A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 2011 1.58
8 CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 2008 1.56
9 TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006 1.54
10 A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002 1.41
11 Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 2008 1.23
12 GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin Cancer Res 2010 1.20
13 Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res 2009 1.19
14 High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS One 2011 1.11
15 Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother 2011 1.09
16 Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. FASEB J 2005 1.04
17 Proteasome inhibition leads to NF-kappaB-independent IL-8 transactivation in human endothelial cells through induction of AP-1. Eur J Immunol 2002 1.00
18 Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol 2011 1.00
19 The cancer stem cell subtype determines immune infiltration of glioblastoma. Stem Cells Dev 2012 0.95
20 FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. J Neurosci 2005 0.92
21 Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation. Eur J Obstet Gynecol Reprod Biol 2008 0.91
22 Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. Brain 2005 0.91
23 Methylation of the p73 gene in gliomas. Acta Neuropathol 2002 0.87
24 Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. Int J Cancer 2006 0.87
25 Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis. Anticancer Res 2012 0.87
26 Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. J Neuroimmunol 2007 0.84
27 Macrophage migration inhibitory factor expression in cervical cancer. J Cancer Res Clin Oncol 2009 0.84
28 Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia 2003 0.83
29 Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions. Arthritis Rheum 2008 0.83
30 Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J Cancer 2012 0.82
31 Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression. Cancer Res 2006 0.82
32 A cell-based luciferase-dependent assay for the quantitative determination of free extracellular adenosine with paracrine signaling activity. J Immunol Methods 2010 0.81
33 Involvement of protein kinase Cdelta and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). Biochem Pharmacol 2003 0.81
34 Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. Arch Gynecol Obstet 2010 0.80
35 The forgotten fallopian tube. Nat Rev Cancer 2011 0.80
36 Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells. Am J Cancer Res 2013 0.80
37 Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: implications for lesion pathogenesis. Brain Behav Immun 2010 0.78
38 Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition. Oncol Rep 2009 0.77
39 Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. Anticancer Drugs 2012 0.76
40 Relevance and mechanism of oxysterol stereospecifity in coronary artery disease. Free Radic Biol Med 2005 0.75
41 Melanoma stem cells: targets for successful therapy? J Dtsch Dermatol Ges 2008 0.75
42 Guidelines are advantageous, though not essential for improved survival among breast cancer patients. Breast Cancer Res Treat 2015 0.75